Neuromod Devices Ltd. Names Tom Maher General Counsel

• Tom Maher joins Neuromod Devices Ltd. with more than twenty-five years of corporate law and business experience in the international life sciences industry, including biopharmaceuticals, biotechnology and medical technology.

DUBLIN, July 3, 2024 /PRNewswire/ — Neuromod Ltd Devices(Neuromod), a global medical technology company that created the first and only FDA-approved device for the treatment of tinnitus, Lenireannounced the nomination today Tom Maher as Chief Legal Counsel, effectively July 5, 2024.

Mr Maher most recently served as Chief Operating Officer, General Counsel and Company Secretary of Amarin Pharmaceuticals Ireland and has a successful track record in three public company management positions.

“I am pleased to announce the appointment of Tom as General Counsel of Neuromod Devices. Tom’s extensive experience in international business and corporate operations in the life sciences industry will be an invaluable asset to Neuromod Devices as we continue to redefine tinnitus care on a global scale.” said Dr. Ross O’NeilFounder and CEO of Neuromod Devices.

Tom Maher joins Neuromod Devices Ltd. with more than twenty-five years of corporate law and business experience in the international life sciences industry, including biopharmaceuticals, biotechnology and medical technology.

In his role as General Counsel, Tom will be responsible for Neuromod’s legal and contractual affairs, corporate transactions, governance and corporate compliance.

Commenting on his appointment, Tom said: “I am delighted to be joining the Neuromod leadership team as the company advances the commercialization of Lenire. I look forward to working with Ross and the entire team to lead the execution of Neuromod’s ambitious strategic plans in 2024 and beyond.”

Mr. Maher’s appointment comes as Neuromod continues to expand Lenire’s global availability. Earlier this year, the organization expanded the number of hearing and tinnitus care practices it works with in United States of America to over 80. Neuromod has also increased the availability of Lenire in Europe by establishing partnerships with additional practices in Spain, Italyand the Principality Monaco.

About Neuromod devices

Founded in 2010, Neuromod Devices is a global medical technology company with offices in IrelandAND United States of AmericaNeuromod specializes in the design and development of neuromodulation technologies to meet the clinical needs of underserved patient populations living with chronic and debilitating conditions.

The primary application area for Neuromod technology is tinnitus. Neuromod has conducted extensive clinical trials in this area, confirming the efficacy of its non-invasive neuromodulation platform in treating this common condition.

for more information visit www.neuromoddevices.com.

About Lenire^®

Lenire^® is the first non-invasive bimodal neuromodulation device for the treatment of tinnitus that has been shown to alleviate and relieve tinnitus in extensive clinical trials.

Lenire^® has a CE certificate confirming the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional Europe and has received a De Novo Approval Grant from the U.S. Food and Drug Administration (FDA).

More details about Lenire®, including a list of suppliers, can be found at www.lenire.com.

Neuromod has also increased the availability of Lenire in Europe by establishing partnerships with additional practices in Spain, Italyand the Principality Monaco.

Photo – https://mma.prnewswire.com/media/2452089/Neuromod_Devices_Tom_Maher.jpg